CBD Life Sciences Inc (PK) (CBDL) 銘柄情報

The people by the dilution shares. Not very smart with track record here. The shares sold daily at these levels all dilution. When it gets stuck again at .00001 and done. They will lose like all shareholders before this r/s have. They will sell all 4.5 billion they increase the a/s to after the r/s.

$CBDL I just checked in on this thing and dilution dilution dilution. Mennie double prints with market maker OTCN plan on the ask. Looks like the Nelsons need some Christmas money but then again they're always need money. Couple years ago when they did this they bought a multimillion dollar houseIn Scottsdale Arizona.

Sure but this one. When dilution never ends. Is not dormant. It has good volume. Dilution is and always has been the problem. Why? They get rich selling shares not CBD.

Not entirely. Some stocks remain dormant.

I said for years the dilution will never stop. Why? They get rich selling shares not CBD. It will end up at .00001 and done yet again. No shareholders have a gain at these levels. Of course dilution like before is filling buys. All anyone has to do is look at all the dilution since 2021. To know it is not very smart to buy shares. They still have billions to sell.

There is an active Reg A selling stock at .0006. That is why the stock will not move. Anyone who buys this is throwing their money away. The Nelsons will not let this move. Too lucrative of a game 

Not this one. They have 4.5 billion shares to dump. Same as before. It will end up like before at .00001. Then like before stuck until next r/s.

When the OTC flash flood hits, all boats will rise, every dog has it's day in the OTC!

A lot of PR's. Yet after 4 years of massive dilution that never ends. Look at last income statement. 167,000 in sales. All this is all talk to sell billions of more shares. They are a no body in the CBD market. Every day they sell new shares to suckers.

The OTC is dead.

CBD Life Sciences Inc. (CBDL) Looking to Acquire a Cannabis Growth License in North Las VegasPress Release | 12/11/2024

Target Acquisition Valued at $10 Million with Projected 2025 Gross Revenue of $5 Million, Positioning CBDL for Explosive Growth in Nevada's Burgeoning Cannabis Market

SCOTTSDALE, AZ / ACCESSWIRE / December 11, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in CBD innovation, announces its intent to acquire a cannabis growth license in North Las Vegas, a move that could serve as a transformative step in the company's evolution. With a target business value of $10 million and a projected $5 million in gross revenue by 2025, this acquisition positions CBDL at the forefront of Nevada's thriving cannabis cultivation market, which is projected to surpass $1.3 billion by 2025.

Expanding beyond its already successful CBD product portfolio, this acquisition will enable CBDL to enter the cannabis cultivation and distribution space, capitalizing on the robust demand for high-quality cannabis products in Nevada and across the nation. This strategic pivot is set to unlock significant revenue potential while solidifying the company's status as a dual-market powerhouse in both CBD and cannabis.

The Nevada Cannabis Market: A Strategic Opportunity

Nevada is one of the most dynamic cannabis markets in the United States, driven by strong consumer demand, progressive regulations, and a booming tourism industry. North Las Vegas, located within Clark County, offers a unique advantage for cannabis cultivation due to its proximity to Las Vegas' 40+ million annual tourists and access to key distribution channels. With legalization trends continuing to sweep the nation, Nevada's cannabis market remains a critical growth hub for companies like CBDL.

Securing a cannabis growth license in this region offers unparalleled potential. Cannabis cultivation facilities in Nevada have demonstrated the ability to generate annual revenues ranging from $1.5 million to $5 million, depending on scale and efficiency. For CBDL, this venture could create new revenue streams and provide significant competitive advantages in an increasingly crowded marketplace.

Diversifying Revenue and Strengthening Market Position

The cannabis growth license acquisition aligns with CBDL's long-term strategy of diversification and growth. In addition to providing a new revenue channel, this venture allows the company to vertically integrate its operations, controlling production quality while reducing costs. Vertical integration is particularly advantageous in the cannabis industry, where consistency, compliance, and quality are key differentiators.

By producing cannabis in-house, CBDL gains greater control over the supply chain and opens doors to additional high-margin opportunities, including:

White-label partnerships with other cannabis brands.

Direct-to-consumer sales through dispensaries.

Product development leveraging CBDL's expertise in formulating premium CBD products.

This expansion also strengthens CBDL's ability to cater to diverse consumer preferences, from recreational cannabis users to medical patients seeking relief through high-quality cannabis products.

Revenue Projections That Excite

As part of this expansion, CBDL anticipates a substantial increase in its revenue trajectory. The company's current growth momentum, evidenced by a 1,405.46% revenue increase since February 2024, underscores its ability to scale effectively and capitalize on new opportunities. The projected $5 million in gross revenue from this cannabis growth license by 2025 could propel CBDL to new heights, allowing it to reinvest in operations, marketing, and product innovation.

Additionally, the Nevada cannabis market benefits from one of the most business-friendly taxation systems in the country, providing further incentives for long-term profitability. Coupled with its flourishing tourism industry and expanding local customer base, this acquisition represents a near-perfect synergy between market opportunity and company capabilities.

Endless Possibilities for Growth and Innovation

The cannabis industry is evolving at an unprecedented pace, with significant advancements in cultivation technology, product innovation, and consumer awareness. By establishing a foothold in North Las Vegas, CBDL can leverage these trends to develop cutting-edge products that appeal to a wide range of consumers. The potential for partnerships with dispensaries, research institutions, and wellness companies further underscores the limitless growth opportunities this acquisition presents.

"This is not just another step for CBD Life Sciences Inc. - it's a leap toward redefining our company's future," said Lisa Nelson, President and CEO of CBDL. "With a cannabis growth license in North Las Vegas, we are positioned to accelerate our growth, diversify our portfolio, and deliver unmatched value to our shareholders."

Looking Ahead: A Bright Future for CBDL

CBDL's entrance into the cannabis cultivation market represents a monumental shift in its operational strategy, but it's only the beginning. As the company continues to explore expansion opportunities in Nevada and other high-growth regions, shareholders and investors can expect exciting updates in the months ahead.

The acquisition of this growth license is more than a business move - it's a testament to CBDL's commitment to innovation, growth, and shareholder value. With the cannabis and CBD markets projected to reach record-breaking revenues in the coming years, CBDL is positioning itself as a trailblazer in the wellness industry.

For more information, please visit CBD Life Sciences Inc.

About CBD Life Sciences Inc.

CBD Life Sciences Inc. (OTC:CBDL) is a leader in the CBD and wellness industries, specializing in premium CBD products and innovative solutions. With a proven track record of growth and a forward-thinking approach, CBDL continues to expand its presence in emerging markets, driving shareholder value and industry leadership.

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

Related Images

SOURCE: CBD Life Sciences Inc.
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Looking-to-Acquire-a-Cannabis-Growth-License-in-North-Las-Vegas?id=461963

Good Morning $CBDL

$CBDL CBD Life Sciences Inc. (CBDL) Looking to Acquire a Cannabis Growth License in North Las Vegas

https://www.accesswire.com/952724/cbd-life-sciences-inc-cbdl-looking-to-acquire-a-cannabis-growth-license-in-north-las-vegas

Target Acquisition Valued at $10 Million with Projected 2025 Gross Revenue of $5 Million, Positioning CBDL for Explosive Growth in Nevada's Burgeoning Cannabis Market

SCOTTSDALE, AZ / ACCESSWIRE / December 11, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in CBD innovation, announces its intent to acquire a cannabis growth license in North Las Vegas, a move that could serve as a transformative step in the company's evolution. With a target business value of $10 million and a projected $5 million in gross revenue by 2025, this acquisition positions CBDL at the forefront of Nevada's thriving cannabis cultivation market, which is projected to surpass $1.3 billion by 2025.

Expanding beyond its already successful CBD product portfolio, this acquisition will enable CBDL to enter the cannabis cultivation and distribution space, capitalizing on the robust demand for high-quality cannabis products in Nevada and across the nation. This strategic pivot is set to unlock significant revenue potential while solidifying the company's status as a dual-market powerhouse in both CBD and cannabis.

The Nevada Cannabis Market: A Strategic Opportunity

Nevada is one of the most dynamic cannabis markets in the United States, driven by strong consumer demand, progressive regulations, and a booming tourism industry. North Las Vegas, located within Clark County, offers a unique advantage for cannabis cultivation due to its proximity to Las Vegas' 40+ million annual tourists and access to key distribution channels. With legalization trends continuing to sweep the nation, Nevada's cannabis market remains a critical growth hub for companies like CBDL.

Securing a cannabis growth license in this region offers unparalleled potential. Cannabis cultivation facilities in Nevada have demonstrated the ability to generate annual revenues ranging from $1.5 million to $5 million, depending on scale and efficiency. For CBDL, this venture could create new revenue streams and provide significant competitive advantages in an increasingly crowded marketplace.

Diversifying Revenue and Strengthening Market Position

The cannabis growth license acquisition aligns with CBDL's long-term strategy of diversification and growth. In addition to providing a new revenue channel, this venture allows the company to vertically integrate its operations, controlling production quality while reducing costs. Vertical integration is particularly advantageous in the cannabis industry, where consistency, compliance, and quality are key differentiators.

By producing cannabis in-house, CBDL gains greater control over the supply chain and opens doors to additional high-margin opportunities, including:

White-label partnerships with other cannabis brands.

Direct-to-consumer sales through dispensaries.

Product development leveraging CBDL's expertise in formulating premium CBD products.

This expansion also strengthens CBDL's ability to cater to diverse consumer preferences, from recreational cannabis users to medical patients seeking relief through high-quality cannabis products.

Revenue Projections That Excite

As part of this expansion, CBDL anticipates a substantial increase in its revenue trajectory. The company's current growth momentum, evidenced by a 1,405.46% revenue increase since February 2024, underscores its ability to scale effectively and capitalize on new opportunities. The projected $5 million in gross revenue from this cannabis growth license by 2025 could propel CBDL to new heights, allowing it to reinvest in operations, marketing, and product innovation.

Additionally, the Nevada cannabis market benefits from one of the most business-friendly taxation systems in the country, providing further incentives for long-term profitability. Coupled with its flourishing tourism industry and expanding local customer base, this acquisition represents a near-perfect synergy between market opportunity and company capabilities.

Endless Possibilities for Growth and Innovation

The cannabis industry is evolving at an unprecedented pace, with significant advancements in cultivation technology, product innovation, and consumer awareness. By establishing a foothold in North Las Vegas, CBDL can leverage these trends to develop cutting-edge products that appeal to a wide range of consumers. The potential for partnerships with dispensaries, research institutions, and wellness companies further underscores the limitless growth opportunities this acquisition presents.

"This is not just another step for CBD Life Sciences Inc. - it's a leap toward redefining our company's future," said Lisa Nelson, President and CEO of CBDL. "With a cannabis growth license in North Las Vegas, we are positioned to accelerate our growth, diversify our portfolio, and deliver unmatched value to our shareholders."

Looking Ahead: A Bright Future for CBDL

CBDL's entrance into the cannabis cultivation market represents a monumental shift in its operational strategy, but it's only the beginning. As the company continues to explore expansion opportunities in Nevada and other high-growth regions, shareholders and investors can expect exciting updates in the months ahead.

The acquisition of this growth license is more than a business move - it's a testament to CBDL's commitment to innovation, growth, and shareholder value. With the cannabis and CBD markets projected to reach record-breaking revenues in the coming years, CBDL is positioning itself as a trailblazer in the wellness industry.

For more information, please visit CBD Life Sciences Inc.

Goon
I have to agree with you on this.one .

Really. So they can sell another billion shares to suckers. Some just never learn.

BIG OPPORTUNITY COMING NEXT WEEK, STAY TUNED $CBDL

Another 16 million in dilution.

For good reason. It still tiny revenues vs billions in dilution. At these levels. Only shares for sale are dilution. 4.5 billion a/s for sale. Dilution has never ended here and never will. They make a lot more selling shares and have now for 4 years.

tweet out "Good morning $CBDL shareholders! Expect next week to one of our biggest yet! The Armed Forces deal should be done! 

We’re also close to reducing the authorized share count to increase shareholder value! Expect big news next week!"

$CBDL huge move is imminent folks. Load and hold. https://x.com/CBDL_StockOTC/status/1865037351228944586

why news out PPS didn't going up? only reason is that PR only say revenue increasing good percent, but not too much number.which they didn't say..

Once again when they dilute billions so it still overvalued. As for this deal. I will believe it when we see it show up on the income statement.

News Alerts https://x.com/CBDL_StockOTC/status/1864738855867289869

Notice they never provide a dollar amount. That is because last filing showed revenues of 167,000.That means revenues still tiny vs billions in dilution. Then do they make profit? It be tiny as well. The way they sell new shares. They could never sell enough CBD to justify that dilution. They make money selling shares. Billions of them not CBD. They have done this since Late 2020 and still are after r/s. At they levels it's new shares filling buys every day.

OTCMKTS: $CBDL Breaking News🚨

CBD Life Sciences Inc. reports a 622% revenue increase from June to November 2024, marking a 1,405% YTD growth driven by strategic launches and market expansion.

$CBDL CBD Life Sciences, Inc. (CBDL) Reports Stunning 622% Revenue Growth From June to November 2024

https://www.accesswire.com/950416/cbd-life-sciences-inc-cbdl-reports-stunning-622-revenue-growth-from-june-to-november-2024

Exploding with momentum: CBDL shatters records with 622% revenue growth in five months, propelling to a 1,405% year-to-date increase-a game-changer in the CBD industry.

SCOTTSDALE, ARIZONA / ACCESSWIRE / December 5, 2024 / CBD Life Sciences, Inc. (CBDL), a leading innovator in the CBD industry, is proud to announce an extraordinary 622% increase in revenue over the five-month period from June to November 2024. This milestone reflects the company's dedication to strategic growth, innovative product development, and expanding market reach.

This revenue surge follows a banner year for CBDL, with year-to-date growth reaching unprecedented levels. Since February 2024, CBDL has experienced a staggering 1,405.46% increase in revenue, further solidifying its position as a dominant force in the CBD and wellness sectors. This success is a testament to CBDL's strategic vision and ability to adapt to the rapidly growing demand for cannabidiol products across various markets.

Key Drivers of Success

Potential Dispensary Acquisition: CBDL has signed a Letter of Intent (LOI) for a strategic partnership involving a cannabis dispensary, opening doors to a new revenue stream and positioning the company as a frontrunner in the retail cannabis market. This move demonstrates CBDL's commitment to seizing high-value opportunities and expanding its influence in the cannabis sector.

Strategic Product Launches: CBDL's product development pipeline has been a critical driver of growth. Flagship products like the Delta-8 Gummies, Pain Relief Cream, Mellow Mornings Nano CBD Coffee Creamer and the veterinarian-designed CBD Horse Paste have captured the attention of consumers and retailers alike, setting new benchmarks for product efficacy and quality.

Retail Expansion: The company's bold move into Walmart Marketplace has significantly expanded its domestic footprint, while plans to launch on Alibaba pave the way for international growth. These initiatives align with CBDL's mission to make its top-tier products accessible to a global audience.

Innovative Science and Technology: CBDL's commitment to leveraging cutting-edge technology, such as nanotechnology, ensures that its products deliver maximum bioavailability and effectiveness. The development of mushroom-based supplements targeting stress reduction and cognitive health showcases the company's ability to diversify its portfolio in response to emerging consumer trends.

Operational Excellence: By streamlining its supply chain and optimizing production processes, CBDL has not only scaled operations but also improved profit margins, ensuring sustainable growth.

Leadership Perspective

Lisa Nelson, President and CEO of CBD Life Sciences, Inc., remarked, "Our 622% revenue growth from June to November is not just a number; it's a reflection of the trust our customers and partners place in us. This achievement is a direct result of our team's unwavering commitment to excellence. As we continue to innovate and enter new markets, our shareholders can anticipate even greater returns on their investment."

Industry Outlook

The global CBD market, which was valued at USD 7.42 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 16.8% from 2024 to 2030. CBDL's robust growth trajectory positions the company as a leader in this booming sector. The market's rapid expansion offers a unique opportunity for investors to capitalize on what is poised to become one of the most lucrative industries in the health and wellness space.

Future Initiatives

CBDL remains steadfast in its commitment to:

Expanding Partnerships: Collaborating with global retailers and exploring strategic alliances to widen distribution networks.

Driving Innovation: Investing in research and development to create groundbreaking products that meet evolving consumer needs.

Enhancing Shareholder Value: Maintaining transparency and delivering consistent financial performance to build investor confidence.

Why Invest in CBDL?

With an impressive track record of growth, a diversified product portfolio, and a strategic roadmap for expansion, CBDL offers an unparalleled investment opportunity. The company's focus on high-growth markets, combined with its operational efficiencies, ensures it is well-positioned to deliver long-term value.

CBDL no dilution since 11/12/2024, O/S shares is 2,782027,499, until today 12/03/2024, no change. CBDL is a very under- valued stock, Its MC only $1,669,216. It will take off any day soon.

What nonsense. They sell shares. Billions over and over. Sale of product tiny. Like I said this will end up diluted back to .0001 again. They could never sell enough CBD to ever justify all the dilution since 2020. It's so over valued even if they sold millions and if they ever make a profit. They make money selling shares to fools not cbd. Has been that way for 4 years. Your nonsense will not change that.

This is a very undervalued stock in OTC markets. Compare the other OTC stocks, this one have much better SS. Revenue has huge potential to increasing, CBDL will break out 0.001 very soon.

Right now it's long way from that. Revenues $167,000 per last income statement. After 4 years and massive dilution that how small the revenues are. CBD is very competitive market. Even if they sold millions. When the o/s the will be billions again. It is still over valued. Who do people think is selling share every day at these levels? The company is.

OTCMKTS: CBDL shareholders! Company recently announced new product projected to do $3mil revenue in the first year! The LOI is closed for the $8mil revenue dispensary.

Only business this scam turdy crappy pos is running is selling shares to unsuspecting newbies. This pile of garbage should have been revoked a long time ago

LOL 4 years they have. Yet revenues just 167,000 and dilution in the billions. Scam share selling is all this is.

$CBDL Targeting a Growing Market:

With the $6B U.S. edibles market booming, CBDL projects $3M in first-year revenue from this targeted product. The growing senior demographic is increasingly turning to natural cannabinoid solutions for cognitive health.

I do not like frauds like this management is. If you do not like the truth too bad. This is going same as before r/s. It will end up at .0001 on billions in dilution again. Wait an see. Heard all the same before last r/s. Another big dilution day. NO one at this level has a gain to sell. The millions of shares are dilution. They have 4.5 billion to sell fools.

https://investorshub.advfn.com/boards/tcloud.aspx

Bid growing, ask hitting, see 7 gone Tomorrow if not Today

Why are you here? If you don't like the company, just leave, no need waste your time to bashing stock.

What nonsense. How is this undervalued? Last income statement showed 167,000 in sales. Vs billions of new shares being sold. It's over valued. Ignore the oast here like you are. When they dilute it down to .00001 yet again. You will be stuck. Just ask shareholders who bought down there before last r/s. Only shares being sold down here are by the company. Same as before.

CBDL is a very undervalued stock, Next year's winner, target PPS could reach 0.25 next year.

OTCMKTS: $CBDL BREAKING NEWS:🚨

CBD Life Sciences Inc. (CBDL) Announces New Delta-8 100MG Gummies Designed to Support Individuals Living With Alzheimer’s

let's break out 0.001 first.

CBD Life Sciences Inc. (CBDL) Announces New Delta-8 100MG Gummies Designed to Support Individuals Living With Alzheimer’s

Targeting a booming $6 billion U.S. edibles market with a projected $3 million in first-year revenue, CBDL delivers an innovative solution for Alzheimer's care.

SCOTTSDALE, ARIZONA / ACCESSWIRE / December 3, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in cannabinoid innovation, proudly announces the launch of its groundbreaking Delta-8 100mg Gummies, specially formulated to support individuals living with Alzheimer's disease. These expertly crafted gummies offer gentle relief and enhanced well-being, addressing the unique needs of patients and their families navigating the challenges of neurodegenerative conditions.

CBD Life Sciences' entry into this specialized segment of the $6 billion U.S. edibles market positions the company as a pioneer in creating products tailored to an underserved demographic. As the population ages and awareness of natural alternatives grows, Delta-8 products are rapidly gaining traction as effective solutions for managing symptoms associated with Alzheimer's and related conditions.

A Product Born from Real Needs and Scientific Innovation

The development of these gummies is deeply rooted in the stories of CBD Life Sciences' clients, who shared how Delta-8 products have positively impacted their loved ones living with Alzheimer's. This heartfelt feedback spurred the creation of a product aimed at addressing symptoms such as anxiety, restlessness, agitation, and mood swings, all while promoting cognitive calmness and overall quality of life.

Delta-8, a naturally occurring cannabinoid, is celebrated for its mild yet effective benefits. Unlike more aggressive treatments, Delta-8 provides a balance of support without overwhelming psychoactive effects, making it an ideal choice for seniors seeking natural relief.

Lisa Nelson, President and CEO of CBD Life Sciences Inc., shared:
"Our mission has always been to create products that genuinely improve lives. With our Delta-8 Gummies, we're addressing a critical gap in Alzheimer's care by offering a natural, effective alternative that families and caregivers can trust. This launch also marks an exciting growth opportunity for our company as we expand into a high-demand market segment."

Revenue and Growth Potential

The Alzheimer's population in the United States is expected to exceed 12.7 million by 2050, creating a significant and growing demand for targeted wellness products. Early projections indicate that this product line could contribute an additional $3 million in revenue within its first year, as CBD Life Sciences continues to meet the rising interest in cannabinoid-based solutions for elderly care.

The senior segment of the edibles market is rapidly emerging as a key growth area. A recent study reported a 300% increase in cannabinoid use among individuals aged 65 and older over the past decade. This demographic is increasingly turning to natural products like Delta-8 for their ability to support physical and cognitive health without the side effects often associated with pharmaceuticals.

Meeting the Needs of an Underserved Market

CBD Life Sciences' Delta-8 Gummies are designed with seniors in mind. These gummies are made from all-natural ingredients, offering easy consumption, precise dosing, and a discreet form factor. Rigorous third-party testing ensures their purity, potency, and consistency, providing families and caregivers with confidence in their safety and efficacy.

The gummies' formulation emphasizes cognitive support and emotional balance, helping to manage the everyday challenges of Alzheimer's while offering peace of mind to those providing care.

CBD Life Sciences: Setting the Standard in Innovation

The launch of the Delta-8 Gummies for Alzheimer's marks another milestone in CBD Life Sciences' remarkable growth trajectory. Since February 2024, the company has achieved a 1405.46% increase in revenue, driven by its commitment to delivering high-quality, innovative products that resonate with consumers.

This latest product also highlights the company's strategic focus on expanding its reach in the health and wellness sector, where demand for cannabinoid-based solutions continues to skyrocket. By addressing the specific needs of aging individuals and their families, CBD Life Sciences solidifies its position as a trusted leader in the industry.

About CBD Life Sciences Inc.

CBD Life Sciences Inc. is a forward-thinking company dedicated to developing and commercializing cannabinoid-based health and wellness solutions. With a diverse product portfolio that includes pain relief creams, nano CBD beverages, and Delta-8 edibles, CBD Life Sciences aims to improve lives while delivering exceptional value to its shareholders.

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information

Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

Related Images

SOURCE: CBD Life Sciences Inc.


View the original press release on accesswire.com

© Copyright 2024 ACCESSWIRE. All Rights Reserved.
https://www.otcmarkets.com/stock/CBDL/news/story?e&id=3063832

Big news this morning!

$CBDL CBD Life Sciences Inc. (CBDL) Announces New Delta-8 100MG Gummies Designed to Support Individuals Living With Alzheimer’s

https://www.accesswire.com/949292/cbd-life-sciences-inc-cbdl-announces-new-delta-8-100mg-gummies-designed-to-support-individuals-living-with-alzheimers

Targeting a booming $6 billion U.S. edibles market with a projected $3 million in first-year revenue, CBDL delivers an innovative solution for Alzheimer's care.

SCOTTSDALE, ARIZONA / ACCESSWIRE / December 3, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in cannabinoid innovation, proudly announces the launch of its groundbreaking Delta-8 100mg Gummies, specially formulated to support individuals living with Alzheimer's disease. These expertly crafted gummies offer gentle relief and enhanced well-being, addressing the unique needs of patients and their families navigating the challenges of neurodegenerative conditions.

CBD Life Sciences' entry into this specialized segment of the $6 billion U.S. edibles market positions the company as a pioneer in creating products tailored to an underserved demographic. As the population ages and awareness of natural alternatives grows, Delta-8 products are rapidly gaining traction as effective solutions for managing symptoms associated with Alzheimer's and related conditions.

A Product Born from Real Needs and Scientific Innovation

The development of these gummies is deeply rooted in the stories of CBD Life Sciences' clients, who shared how Delta-8 products have positively impacted their loved ones living with Alzheimer's. This heartfelt feedback spurred the creation of a product aimed at addressing symptoms such as anxiety, restlessness, agitation, and mood swings, all while promoting cognitive calmness and overall quality of life.

Delta-8, a naturally occurring cannabinoid, is celebrated for its mild yet effective benefits. Unlike more aggressive treatments, Delta-8 provides a balance of support without overwhelming psychoactive effects, making it an ideal choice for seniors seeking natural relief.

Lisa Nelson, President and CEO of CBD Life Sciences Inc., shared:
"Our mission has always been to create products that genuinely improve lives. With our Delta-8 Gummies, we're addressing a critical gap in Alzheimer's care by offering a natural, effective alternative that families and caregivers can trust. This launch also marks an exciting growth opportunity for our company as we expand into a high-demand market segment."

Revenue and Growth Potential

The Alzheimer's population in the United States is expected to exceed 12.7 million by 2050, creating a significant and growing demand for targeted wellness products. Early projections indicate that this product line could contribute an additional $3 million in revenue within its first year, as CBD Life Sciences continues to meet the rising interest in cannabinoid-based solutions for elderly care.

The senior segment of the edibles market is rapidly emerging as a key growth area. A recent study reported a 300% increase in cannabinoid use among individuals aged 65 and older over the past decade. This demographic is increasingly turning to natural products like Delta-8 for their ability to support physical and cognitive health without the side effects often associated with pharmaceuticals.

Meeting the Needs of an Underserved Market

CBD Life Sciences' Delta-8 Gummies are designed with seniors in mind. These gummies are made from all-natural ingredients, offering easy consumption, precise dosing, and a discreet form factor. Rigorous third-party testing ensures their purity, potency, and consistency, providing families and caregivers with confidence in their safety and efficacy.

The gummies' formulation emphasizes cognitive support and emotional balance, helping to manage the everyday challenges of Alzheimer's while offering peace of mind to those providing care.

CBD Life Sciences: Setting the Standard in Innovation

The launch of the Delta-8 Gummies for Alzheimer's marks another milestone in CBD Life Sciences' remarkable growth trajectory. Since February 2024, the company has achieved a 1405.46% increase in revenue, driven by its commitment to delivering high-quality, innovative products that resonate with consumers.

This latest product also highlights the company's strategic focus on expanding its reach in the health and wellness sector, where demand for cannabinoid-based solutions continues to skyrocket. By addressing the specific needs of aging individuals and their families, CBD Life Sciences solidifies its position as a trusted leader in the industry.

small sell, no dilution Today.

I agree to .0001 with massive dilution. Some just refuse to see the facts. At these levels after the r/s. They only ones selling millions of shares is the company.

OTCMKTS: $CBDL BIG WEEK, NEWS ALERTS

CBD Life Sciences Inc. is set for growth as federal marijuana legalization nears, boasting a 1405% revenue surge since early 2024.